SEC Form 4 · accession 0001104659-16-145304
Syros Pharmaceuticals, Inc. · SYRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Philip A Sharp
Director
Period of report
Sep 15, 2016
Accepted (ET)
Sep 19, 2016 · 6:56 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001556263
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $12.59 | Sep 15, 2016 | A | 22,000 | A | — | Sep 14, 2026 | Common Stock | 22,000 | 22,000 | D |
Explanation of responses
- F1The option becomes exercisable as to 16.66% of the shares underlying the award on the six month anniversary of the award, with the remainder vesting in equal monthly installments of 2.77% of the shares underlying the award until the third anniversary of the date of the award, subject to Dr. Sharp's continued service as a director through each applicable vesting date.